Compare Neurocrine Biosciences Inc (NBIX) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs SiTime Corporation — how do they compare? Neurocrine Biosciences Inc trades at $156.06 (market cap $16.46B), while SiTime Corporation trades at $679.01 (market cap $20.05B). The key difference: SiTime Corporation is the larger of the two by market cap, and SiTime Corporation is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | SITM | |
|---|---|---|
Market Cap | $16.46B | $20.05B |
Sector | Health | Technology |
52-Week High | $185.50 | $901.60 |
52-Week Low | $123.10 | $212.77 |
Enterprise Value | $16.48B | $19.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.
Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.
SITM trades at $680.52, down 1.37% on the day, with a bullish technical outlook supported by moving averages and key resistance at $687. The company reported strong Q2 2026 earnings of $2.34 per share, beating estimates, with revenue surging 127% year-over-year driven by AI infrastructure demand. Analyst consensus is unanimously bullish with a $870 price target, reflecting optimism around the Renesas acquisition and AI timing growth.
The outlook for SITM is positive given robust earnings beats, AI-driven revenue expansion, and solid institutional support. However, risks include premium valuation multiples, integration challenges from the Renesas deal, and dependence on cyclical tech spending. Investors should weigh high growth potential against execution risks in a competitive semiconductor market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
